ABO Incompatibility Living Donor Kidney Transplant in Malaysia: Multicenter Experiences and Outcomes (TTS 2026) - Sep 17, 2026 - Abstract #P4.720; Pres time: Sep 22, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P4; "Regarding desensitisation therapy, 66.4% received rituximab, 79% underwent pre-transplant DFPP, 41.6% had pre-transplant plasma exchange, 20.9% received immunoadsorption therapy, and 55.0% received IVIG. As for induction therapy, 75.8% received basiliximab, 23.4% received thymoglobulin, and 0.8% received both therapies... ABOi kidney transplant is feasible and safe, with improved success when patients receive adequate pre-transplant desensitisation therapy, resulting in favourable graft and patient outcomes in our cohort."
Clinical • Transplantation
|
|
Maisarah Jalalonmuhali1; Premila Peraba2; Chee Loong Chong2; Seow Yeing Yee2; Mohamad Zaimi Abdul Wahab2; Zhi Qing Yeow1; Alvin Wei Xian Chin1; Yuan Zhang Choo1; Rosnawati Yahya3; Devamalar Simatherai4; Boon Cheak Bee4; Siti Hafizah Mohammad Ismail4; Kok Peng Ng1; Soo Kun Lim1
|